IMRX vs. GOSS
IMRX (Immuneering Corporation) and GOSS (Gossamer Bio, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, IMRX returned -19.59%/yr vs -47.62%/yr for GOSS. At a 0.17 correlation, their price movements are largely independent.
Performance
IMRX vs. GOSS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IMRX achieves a -30.85% return, which is significantly higher than GOSS's -93.93% return.
IMRX
- 1D
- 6.31%
- 1M
- -15.51%
- YTD
- -30.85%
- 6M
- -32.49%
- 1Y
- 132.14%
- 3Y*
- -19.59%
- 5Y*
- —
- 10Y*
- —
GOSS
- 1D
- -5.94%
- 1M
- -46.26%
- YTD
- -93.93%
- 6M
- -94.49%
- 1Y
- -84.57%
- 3Y*
- -47.62%
- 5Y*
- -53.34%
- 10Y*
- —
IMRX vs. GOSS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
IMRX Immuneering Corporation | -30.85% | 199.09% | -70.07% | 51.55% | -70.01% | -8.07% |
GOSS Gossamer Bio, Inc. | -93.93% | 242.69% | -0.87% | -57.95% | -80.81% | 43.89% |
Correlation
The correlation between IMRX and GOSS is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.13 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Aug 2, 2021 | 0.17 |
Fundamentals
IMRX:
$294.20M
GOSS:
$44.09M
IMRX:
-$293.00
GOSS:
-$0.79
IMRX:
$0.00
GOSS:
$55.54M
IMRX:
-$698.89K
GOSS:
$38.36M
IMRX:
-$15.38B
GOSS:
-$171.46M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IMRX vs. GOSS — Risk / Return Rank
IMRX
GOSS
IMRX vs. GOSS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Immuneering Corporation (IMRX) and Gossamer Bio, Inc. (GOSS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IMRX | GOSS | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.07 | -0.66 | +1.73 |
Sortino ratioReturn per unit of downside risk | 2.16 | -0.47 | +2.64 |
Omega ratioGain probability vs. loss probability | 1.31 | 0.92 | +0.39 |
Calmar ratioReturn relative to maximum drawdown | 2.40 | -0.89 | +3.29 |
Martin ratioReturn relative to average drawdown | 3.98 | -1.65 | +5.63 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IMRX | GOSS | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.07 | -0.66 | +1.73 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.52 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.21 | -0.50 | +0.28 |
Drawdowns
IMRX vs. GOSS - Drawdown Comparison
The maximum IMRX drawdown since its inception was -96.86%, roughly equal to the maximum GOSS drawdown of -99.30%. Use the drawdown chart below to compare losses from any high point for IMRX and GOSS.
Loading charts...
Drawdown Indicators
| IMRX | GOSS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.86% | -99.30% | +2.44% |
Max Drawdown (1Y)Largest decline over 1 year | -55.35% | -95.03% | +39.68% |
Max Drawdown (3Y)Largest decline over 3 years | -90.98% | -95.03% | +4.05% |
Max Drawdown (5Y)Largest decline over 5 years | — | -98.73% | — |
Current DrawdownCurrent decline from peak | -86.14% | -99.30% | +13.16% |
Average DrawdownAverage peak-to-trough decline | -77.60% | -71.38% | -6.22% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.32% | 51.26% | -17.94% |
Volatility
IMRX vs. GOSS - Volatility Comparison
The current volatility for Immuneering Corporation (IMRX) is 32.23%, while Gossamer Bio, Inc. (GOSS) has a volatility of 62.06%. This indicates that IMRX experiences smaller price fluctuations and is considered to be less risky than GOSS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IMRX | GOSS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 32.23% | 62.06% | -29.83% |
Volatility (6M)Calculated over the trailing 6-month period | 78.61% | 182.68% | -104.07% |
Volatility (1Y)Calculated over the trailing 1-year period | 123.87% | 129.41% | -5.54% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 114.62% | 103.05% | +11.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 114.62% | 93.59% | +21.03% |
Dividends
IMRX vs. GOSS - Dividend Comparison
Neither IMRX nor GOSS has paid dividends to shareholders.
Financials
IMRX vs. GOSS - Financials Comparison
This section allows you to compare key financial metrics between Immuneering Corporation and Gossamer Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
IMRX and GOSS have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GOSS has higher volatility (62.06%) compared to IMRX (32.23%). In terms of maximum drawdown, IMRX dropped -96.86% vs GOSS's -99.30%.
IMRX currently has the higher Sharpe Ratio (1.07 vs -0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IMRX and GOSS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer